These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 26009011)

  • 1. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.
    Alexandrova EM; Xu S; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2683. PubMed ID: 28300840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion.
    Schulz-Heddergott R; Stark N; Edmunds SJ; Li J; Conradi LC; Bohnenberger H; Ceteci F; Greten FR; Dobbelstein M; Moll UM
    Cancer Cell; 2018 Aug; 34(2):298-314.e7. PubMed ID: 30107178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.
    Schulz-Heddergott R; Moll UM
    Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29875343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
    Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
    Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
    Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
    Front Oncol; 2021; 11():642603. PubMed ID: 34178628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
    Tutuska K; Parrilla-Monge L; Di Cesare E; Nemajerova A; Moll UM
    Cell Death Dis; 2020 Apr; 11(4):274. PubMed ID: 32332697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion.
    Zhang S; Wang C; Ma B; Xu M; Xu S; Liu J; Tian Y; Fu Y; Luo Y
    Cell Rep; 2020 Jul; 32(1):107879. PubMed ID: 32640214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma.
    Jethwa A; Słabicki M; Hüllein J; Jentzsch M; Dalal V; Rabe S; Wagner L; Walther T; Klapper W; ; Bohnenberger H; Rettel M; Lu J; Smits AH; Stein F; Savitski MM; Huber W; Aylon Y; Oren M; Zenz T
    Blood; 2018 Jun; 131(25):2789-2802. PubMed ID: 29653964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gambogic acid counteracts mutant p53 stability by inducing autophagy.
    Foggetti G; Ottaggio L; Russo D; Monti P; Degan P; Fronza G; Menichini P
    Biochim Biophys Acta Mol Cell Res; 2017 Feb; 1864(2):382-392. PubMed ID: 27899303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival.
    Foggetti G; Ottaggio L; Russo D; Mazzitelli C; Monti P; Degan P; Miele M; Fronza G; Menichini P
    Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30745455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
    Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
    J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1.
    Tong X; Xu D; Mishra RK; Jones RD; Sun L; Schiltz GE; Liao J; Yang GY
    J Biol Chem; 2021; 296():100098. PubMed ID: 33208462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
    Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
    J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNAJA1 promotes cancer metastasis through interaction with mutant p53.
    Kaida A; Yamamoto S; Parrales A; Young ED; Ranjan A; Alalem MA; Morita KI; Oikawa Y; Harada H; Ikeda T; Thomas SM; Diaz FJ; Iwakuma T
    Oncogene; 2021 Aug; 40(31):5013-5025. PubMed ID: 34183772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
    Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
    Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated mutant p53 promotes cancer cell survival upon glutamine deprivation through p21 induction.
    Tran TQ; Lowman XH; Reid MA; Mendez-Dorantes C; Pan M; Yang Y; Kong M
    Oncogene; 2017 Apr; 36(14):1991-2001. PubMed ID: 27721412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
    Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
    Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.